BHV8000-301 is a clinical research study evaluating an investigational oral medication, BHV-8000, to determine whether it can slow clinical disease progression of Parkinson’s disease (PD).
You may be eligible if you:
- Are 40 to 80 years of age
- Have been diagnosed, or have a probable diagnosis of Parkinson’s disease
- Have not started any medications to manage PD symptoms
- There are other eligibility requirements which will be assessed by the research staff.
If you are interested in learning more or to see if you may qualify, please contact the Neurology Center of New England research department at 781-551-5812 opt. 4 or ResearchNCNE@neurocenterne.com.